← 返回

大海捞针:肿瘤免疫学与免疫治疗中新靶点的功能筛选

英文原题:Finding a needle in a haystack: functional screening for novel targets in cancer immunology and immunotherapies.

查看英文原题

Finding a needle in a haystack: functional screening for novel targets in cancer immunology and immunotherapies.

PubMed 2025/01/25(内容时间) Oncogene Q1 · IF 9.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

全基因组功能性基因筛选已在生物医学领域得到广泛应用,使在基因水平上大海捞针成为可能。在癌症研究中,基因突变与肿瘤的发展、转移和复发密切相关,利用诸如成簇规律间隔短回文重复序列(CRISPR)等最先进且强大的筛选技术来搜寻最关键的基因或编码产物,为我们进一步细化癌症图谱提供了新的可能,并为癌症患者的治疗提供了新的可能性。利用CRISPR筛选最关键的基因或编码产物,进一步完善了癌症图谱,并为癌症患者的治疗提供了新的可能性。免疫疗法作为一种极具前景的癌症治疗方法,已在临床上得到广泛验证,但它只能满足一小部分癌症患者的需求。寻找新的免疫治疗靶点是肿瘤免疫治疗未来的关键。在本文中,我们从不同角度重新审视了功能性筛选在癌症免疫学中的应用,从多样化的体外和体内筛选模型的选择,到针对CAR-T 细胞的潜在免疫检查点及增效基因的筛选。这些数据将为癌症患者提供新的治疗线索。

展开英文摘要原文

Genome-wide functional genetic screening has been widely used in the biomedicine field, which makes it possible to find a needle in a haystack at the genetic level. In cancer research, gene mutations are closely related to tumor development, metastasis, and recurrence, and the use of state-of-the-art powerful screening technologies, such as clustered regularly interspaced short palindromic repeat (CRISPR), to search for the most critical genes or coding products provides us with a new possibility to further refine the cancer mapping and provide new possibilities for the treatment of cancer patients.

The use of CRISPR screening for the most critical genes or coding products has further refined the cancer atlas and provided new possibilities for the treatment of cancer patients. Immunotherapy, as a highly promising cancer treatment method, has been widely validated in the clinic, but it could only meet the needs of a small proportion of cancer patients. Finding new immunotherapy targets is the key to the future of tumor immunotherapy.

Here, we revisit the application of functional screening in cancer immunology from different perspectives, from the selection of diverse in vitro and in vivo screening models to the screening of potential immune checkpoints and potentiating genes for CAR-T cells. The data will offer fresh therapeutic clues for cancer patients.

论文信息

作者
Du Y、Yang Y、Zheng B、Zhang Q、Zhou S、Zhao L
第一作者单位
Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, West China Second Hospital, State Key Laboratory of Biotherapy, and Department of Neurosurgery, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, P. R. China.China
通讯作者单位
Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, West China Second Hospital, State Key Laboratory of Biotherapy, and Department of Neurosurgery, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, P. R. China. ljzhao89@163.com.China
文献类型
综述
期刊
Oncogene2025 Mar
原文标识
PubMed 39863748 · DOI 10.1038/s41388-025-03273-8